A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

BACKGROUND: About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates between 36-60%. Unfortunately only 20% of patients are resectable at...

Descripción completa

Detalles Bibliográficos
Autores principales: Snoeren, Nikol, Voest, Emile E, Bergman, Andre M, Dalesio, Otilia, Verheul, Henk M, Tollenaar, Rob AEM, van der Sijp, Joost RM, Schouten, Sander B, Rinkes, Inne HM Borel, van Hillegersberg, R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958953/
https://www.ncbi.nlm.nih.gov/pubmed/20937118
http://dx.doi.org/10.1186/1471-2407-10-545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958953/
https://www.ncbi.nlm.nih.gov/pubmed/20937118
http://dx.doi.org/10.1186/1471-2407-10-545

Ejemplares similares